



TECHNICAL BULLETIN

DISCONTINUED TEST

NOTIFICATION DATE: March 19, 2021

EFFECTIVE DATE: March 22, 2021

Infliximab Concentration and Anti-Infliximab Antibody (INFLIXMAB)

On the effective date the **Infliximab Concentration and Anti-Infliximab Antibody** test will no longer be available to order at LabCorp and will be discontinued. The recommended alternative test is Prometheus **Anser® IFX**

Computer Interface Code: [PDM # 5963016](#)

Test Order: [INFLIXMAB](#)

Recommended Alternative Test: [PrometheusAnser® IFX Test](#)

The **Prometheus Anser® IFX** test includes serum infliximab concentration (IFX) and antibodies to infliximab (ATI)

Computer Interface Code: [PDM # 1759071](#)

Test Order: [ANSERIFX](#)

Methodology: [Electrochemiluminescence Immunoassay \(ECLIA\)](#)

Reference Values: [Serum infliximab \(IFX\) concentration: <1.0 ug/mL](#)
[Antibody to infliximab \(ATI\) concentration: <3.1 U/mL](#)

Specimen Requirements

Container/Tube: [Gold Top Tube](#)

Specimen Volume: [2 mL Serum \(0.5 mL min\)](#)

[If you have any questions, please contact Client Services at \(516\) 719-1100.](#)